Skip to main content

TYVASO is approved for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve the ability to exercise.

Skip to main content
Hamburger button
Close button
TYVASO helped lower the risk of PH-ILD getting worse by 39% in a 16 week clinical study.
TYVASO helped lower the risk of PH-ILD getting worse by 39% in a 16 week clinical study.

REDUCING THE RISK OF PH-ILD GETTING WORSE

TYVASO has been shown to reduce disease worsening

During the 16-week study, TYVASO helped lower the risk of PH-ILD getting worse by 39%.

Learn more about taking TYVASO.